nodes	percent_of_prediction	percent_of_DWPC	metapath
Epinephrine—TNF—psoriasis	0.531	1	CbGaD
Epinephrine—CYP1A2—Clobetasol propionate—psoriasis	0.0571	0.248	CbGbCtD
Epinephrine—CYP1A2—Methoxsalen—psoriasis	0.03	0.13	CbGbCtD
Epinephrine—CYP3A4—Calcitriol—psoriasis	0.0202	0.0878	CbGbCtD
Epinephrine—CYP2C9—Cholecalciferol—psoriasis	0.0179	0.0778	CbGbCtD
Epinephrine—CYP3A4—Methoxsalen—psoriasis	0.0157	0.0683	CbGbCtD
Epinephrine—CYP2C9—Cyclosporine—psoriasis	0.0118	0.0511	CbGbCtD
Epinephrine—CYP3A4—Cholecalciferol—psoriasis	0.0104	0.0452	CbGbCtD
Epinephrine—CYP3A4—Mycophenolate mofetil—psoriasis	0.00902	0.0392	CbGbCtD
Epinephrine—CYP3A4—Triamcinolone—psoriasis	0.00902	0.0392	CbGbCtD
Epinephrine—CYP2C9—Dexamethasone—psoriasis	0.00774	0.0337	CbGbCtD
Epinephrine—CYP3A4—Betamethasone—psoriasis	0.00774	0.0337	CbGbCtD
Epinephrine—CYP3A4—Prednisolone—psoriasis	0.00764	0.0332	CbGbCtD
Epinephrine—CYP3A4—Hydrocortisone—psoriasis	0.00724	0.0315	CbGbCtD
Epinephrine—CYP3A4—Prednisone—psoriasis	0.00721	0.0314	CbGbCtD
Epinephrine—CYP3A4—Cyclosporine—psoriasis	0.00684	0.0297	CbGbCtD
Epinephrine—CYP3A4—Dexamethasone—psoriasis	0.0045	0.0196	CbGbCtD
Epinephrine—Erythema—Hydroxyurea—psoriasis	0.00038	0.00256	CcSEcCtD
Epinephrine—Hypokalaemia—Mycophenolate mofetil—psoriasis	0.00038	0.00256	CcSEcCtD
Epinephrine—Nausea—Beclomethasone—psoriasis	0.000379	0.00255	CcSEcCtD
Epinephrine—Extravasation—Methotrexate—psoriasis	0.000374	0.00251	CcSEcCtD
Epinephrine—Skin exfoliation—Prednisone—psoriasis	0.000372	0.0025	CcSEcCtD
Epinephrine—Psychotic disorder—Hydrocortisone—psoriasis	0.000372	0.0025	CcSEcCtD
Epinephrine—Haemoglobin—Mycophenolic acid—psoriasis	0.000368	0.00247	CcSEcCtD
Epinephrine—Haemorrhage—Mycophenolic acid—psoriasis	0.000366	0.00246	CcSEcCtD
Epinephrine—Hypoaesthesia—Mycophenolic acid—psoriasis	0.000364	0.00245	CcSEcCtD
Epinephrine—Hallucination—Mycophenolic acid—psoriasis	0.000364	0.00245	CcSEcCtD
Epinephrine—Sweating increased—Cyclosporine—psoriasis	0.00036	0.00242	CcSEcCtD
Epinephrine—Insomnia—Acitretin—psoriasis	0.000358	0.00241	CcSEcCtD
Epinephrine—Paraesthesia—Acitretin—psoriasis	0.000355	0.00239	CcSEcCtD
Epinephrine—Somnolence—Acitretin—psoriasis	0.000352	0.00236	CcSEcCtD
Epinephrine—Pulmonary oedema—Prednisone—psoriasis	0.000347	0.00233	CcSEcCtD
Epinephrine—Hypokalaemia—Hydrocortisone—psoriasis	0.000346	0.00233	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Acitretin—psoriasis	0.000341	0.0023	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Fluocinolone Acetonide—psoriasis	0.00034	0.00229	CcSEcCtD
Epinephrine—Hyperglycaemia—Cyclosporine—psoriasis	0.000334	0.00224	CcSEcCtD
Epinephrine—Dizziness—Methoxsalen—psoriasis	0.00033	0.00222	CcSEcCtD
Epinephrine—Sweating increased—Prednisolone—psoriasis	0.000328	0.00221	CcSEcCtD
Epinephrine—Arrhythmia—Mycophenolic acid—psoriasis	0.000327	0.0022	CcSEcCtD
Epinephrine—Hyperglycaemia—Mycophenolate mofetil—psoriasis	0.000326	0.00219	CcSEcCtD
Epinephrine—Acute coronary syndrome—Cyclosporine—psoriasis	0.000325	0.00219	CcSEcCtD
Epinephrine—Renal failure—Cyclosporine—psoriasis	0.000324	0.00218	CcSEcCtD
Epinephrine—Myocardial infarction—Cyclosporine—psoriasis	0.000323	0.00217	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—psoriasis	0.000322	0.00216	CcSEcCtD
Epinephrine—Mental disorder—Mycophenolic acid—psoriasis	0.000321	0.00216	CcSEcCtD
Epinephrine—Sweating increased—Hydrocortisone—psoriasis	0.00032	0.00215	CcSEcCtD
Epinephrine—Psychotic disorder—Dexamethasone—psoriasis	0.000317	0.00213	CcSEcCtD
Epinephrine—Psychotic disorder—Betamethasone—psoriasis	0.000317	0.00213	CcSEcCtD
Epinephrine—Acute coronary syndrome—Mycophenolate mofetil—psoriasis	0.000317	0.00213	CcSEcCtD
Epinephrine—Renal failure—Mycophenolate mofetil—psoriasis	0.000316	0.00213	CcSEcCtD
Epinephrine—Myocardial infarction—Mycophenolate mofetil—psoriasis	0.000315	0.00212	CcSEcCtD
Epinephrine—Tension—Mycophenolic acid—psoriasis	0.000313	0.0021	CcSEcCtD
Epinephrine—Skin exfoliation—Methotrexate—psoriasis	0.000311	0.00209	CcSEcCtD
Epinephrine—Nervousness—Mycophenolic acid—psoriasis	0.000309	0.00208	CcSEcCtD
Epinephrine—Sweating—Mycophenolate mofetil—psoriasis	0.000308	0.00207	CcSEcCtD
Epinephrine—Nervous system disorder—Hydroxyurea—psoriasis	0.000305	0.00205	CcSEcCtD
Epinephrine—Skin disorder—Hydroxyurea—psoriasis	0.000302	0.00203	CcSEcCtD
Epinephrine—Sweating increased—Triamcinolone—psoriasis	0.000302	0.00203	CcSEcCtD
Epinephrine—Haemoglobin—Cyclosporine—psoriasis	0.000298	0.002	CcSEcCtD
Epinephrine—Nausea—Methoxsalen—psoriasis	0.000296	0.00199	CcSEcCtD
Epinephrine—Haemorrhage—Cyclosporine—psoriasis	0.000296	0.00199	CcSEcCtD
Epinephrine—Acute coronary syndrome—Prednisolone—psoriasis	0.000296	0.00199	CcSEcCtD
Epinephrine—Hypokalaemia—Betamethasone—psoriasis	0.000296	0.00199	CcSEcCtD
Epinephrine—Hypokalaemia—Dexamethasone—psoriasis	0.000296	0.00199	CcSEcCtD
Epinephrine—Hypoaesthesia—Cyclosporine—psoriasis	0.000295	0.00198	CcSEcCtD
Epinephrine—Myocardial infarction—Prednisolone—psoriasis	0.000294	0.00198	CcSEcCtD
Epinephrine—Agitation—Mycophenolic acid—psoriasis	0.000293	0.00197	CcSEcCtD
Epinephrine—Haemoglobin—Mycophenolate mofetil—psoriasis	0.00029	0.00195	CcSEcCtD
Epinephrine—Pulmonary oedema—Methotrexate—psoriasis	0.00029	0.00195	CcSEcCtD
Epinephrine—Acute coronary syndrome—Hydrocortisone—psoriasis	0.000289	0.00194	CcSEcCtD
Epinephrine—Haemorrhage—Mycophenolate mofetil—psoriasis	0.000289	0.00194	CcSEcCtD
Epinephrine—Hallucination—Mycophenolate mofetil—psoriasis	0.000287	0.00193	CcSEcCtD
Epinephrine—Hypoaesthesia—Mycophenolate mofetil—psoriasis	0.000287	0.00193	CcSEcCtD
Epinephrine—Myocardial infarction—Hydrocortisone—psoriasis	0.000287	0.00193	CcSEcCtD
Epinephrine—Vomiting—Calcitriol—psoriasis	0.000283	0.0019	CcSEcCtD
Epinephrine—Palpitations—Mycophenolic acid—psoriasis	0.000282	0.00189	CcSEcCtD
Epinephrine—Psychotic disorder—Prednisone—psoriasis	0.000276	0.00186	CcSEcCtD
Epinephrine—Somnolence—Hydroxyurea—psoriasis	0.000276	0.00186	CcSEcCtD
Epinephrine—Hypertension—Mycophenolic acid—psoriasis	0.000275	0.00185	CcSEcCtD
Epinephrine—Flushing—Cyclosporine—psoriasis	0.000275	0.00185	CcSEcCtD
Epinephrine—Sweating increased—Betamethasone—psoriasis	0.000274	0.00184	CcSEcCtD
Epinephrine—Sweating increased—Dexamethasone—psoriasis	0.000274	0.00184	CcSEcCtD
Epinephrine—Acute coronary syndrome—Triamcinolone—psoriasis	0.000272	0.00183	CcSEcCtD
Epinephrine—Chest pain—Mycophenolic acid—psoriasis	0.000271	0.00182	CcSEcCtD
Epinephrine—Haemoglobin—Prednisolone—psoriasis	0.000271	0.00182	CcSEcCtD
Epinephrine—Myocardial infarction—Triamcinolone—psoriasis	0.000271	0.00182	CcSEcCtD
Epinephrine—Haemorrhage—Prednisolone—psoriasis	0.000269	0.00181	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.000269	0.00181	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000268	0.0018	CcSEcCtD
Epinephrine—Arrhythmia—Cyclosporine—psoriasis	0.000265	0.00178	CcSEcCtD
Epinephrine—Haemoglobin—Hydrocortisone—psoriasis	0.000265	0.00178	CcSEcCtD
Epinephrine—Nausea—Calcitriol—psoriasis	0.000264	0.00178	CcSEcCtD
Epinephrine—Haemorrhage—Hydrocortisone—psoriasis	0.000263	0.00177	CcSEcCtD
Epinephrine—Hallucination—Hydrocortisone—psoriasis	0.000262	0.00176	CcSEcCtD
Epinephrine—Dizziness—Acitretin—psoriasis	0.000262	0.00176	CcSEcCtD
Epinephrine—Dizziness—Fluocinolone Acetonide—psoriasis	0.000261	0.00175	CcSEcCtD
Epinephrine—Mental disorder—Cyclosporine—psoriasis	0.000259	0.00174	CcSEcCtD
Epinephrine—Arrhythmia—Mycophenolate mofetil—psoriasis	0.000258	0.00174	CcSEcCtD
Epinephrine—Hypokalaemia—Prednisone—psoriasis	0.000258	0.00173	CcSEcCtD
Epinephrine—Nervous system disorder—Mycophenolic acid—psoriasis	0.000255	0.00172	CcSEcCtD
Epinephrine—Tachycardia—Mycophenolic acid—psoriasis	0.000254	0.00171	CcSEcCtD
Epinephrine—Hyperglycaemia—Betamethasone—psoriasis	0.000253	0.0017	CcSEcCtD
Epinephrine—Hyperglycaemia—Dexamethasone—psoriasis	0.000253	0.0017	CcSEcCtD
Epinephrine—Mental disorder—Mycophenolate mofetil—psoriasis	0.000253	0.0017	CcSEcCtD
Epinephrine—Tension—Cyclosporine—psoriasis	0.000253	0.0017	CcSEcCtD
Epinephrine—Skin disorder—Mycophenolic acid—psoriasis	0.000253	0.0017	CcSEcCtD
Epinephrine—Vomiting—Acitretin—psoriasis	0.000251	0.00169	CcSEcCtD
Epinephrine—Hyperhidrosis—Mycophenolic acid—psoriasis	0.000251	0.00169	CcSEcCtD
Epinephrine—Vomiting—Fluocinolone Acetonide—psoriasis	0.000251	0.00169	CcSEcCtD
Epinephrine—Nervousness—Cyclosporine—psoriasis	0.00025	0.00168	CcSEcCtD
Epinephrine—Haemoglobin—Triamcinolone—psoriasis	0.000249	0.00167	CcSEcCtD
Epinephrine—Haemorrhage—Triamcinolone—psoriasis	0.000248	0.00167	CcSEcCtD
Epinephrine—Acute coronary syndrome—Dexamethasone—psoriasis	0.000247	0.00166	CcSEcCtD
Epinephrine—Acute coronary syndrome—Betamethasone—psoriasis	0.000247	0.00166	CcSEcCtD
Epinephrine—Tension—Mycophenolate mofetil—psoriasis	0.000247	0.00166	CcSEcCtD
Epinephrine—Myocardial infarction—Dexamethasone—psoriasis	0.000246	0.00165	CcSEcCtD
Epinephrine—Myocardial infarction—Betamethasone—psoriasis	0.000246	0.00165	CcSEcCtD
Epinephrine—Nervousness—Mycophenolate mofetil—psoriasis	0.000244	0.00164	CcSEcCtD
Epinephrine—Cerebrovascular accident—Methotrexate—psoriasis	0.000241	0.00162	CcSEcCtD
Epinephrine—Arrhythmia—Prednisolone—psoriasis	0.000241	0.00162	CcSEcCtD
Epinephrine—Sweating increased—Prednisone—psoriasis	0.000238	0.0016	CcSEcCtD
Epinephrine—Agitation—Cyclosporine—psoriasis	0.000237	0.00159	CcSEcCtD
Epinephrine—Insomnia—Mycophenolic acid—psoriasis	0.000235	0.00158	CcSEcCtD
Epinephrine—Arrhythmia—Hydrocortisone—psoriasis	0.000235	0.00158	CcSEcCtD
Epinephrine—Nausea—Acitretin—psoriasis	0.000235	0.00158	CcSEcCtD
Epinephrine—Erythema—Prednisolone—psoriasis	0.000235	0.00158	CcSEcCtD
Epinephrine—Nausea—Fluocinolone Acetonide—psoriasis	0.000234	0.00158	CcSEcCtD
Epinephrine—Paraesthesia—Mycophenolic acid—psoriasis	0.000234	0.00157	CcSEcCtD
Epinephrine—Somnolence—Mycophenolic acid—psoriasis	0.000231	0.00155	CcSEcCtD
Epinephrine—Agitation—Mycophenolate mofetil—psoriasis	0.000231	0.00155	CcSEcCtD
Epinephrine—Mental disorder—Hydrocortisone—psoriasis	0.000231	0.00155	CcSEcCtD
Epinephrine—Erythema—Hydrocortisone—psoriasis	0.000229	0.00154	CcSEcCtD
Epinephrine—Haemoglobin—Dexamethasone—psoriasis	0.000226	0.00152	CcSEcCtD
Epinephrine—Haemoglobin—Betamethasone—psoriasis	0.000226	0.00152	CcSEcCtD
Epinephrine—Haemorrhage—Dexamethasone—psoriasis	0.000225	0.00151	CcSEcCtD
Epinephrine—Haemorrhage—Betamethasone—psoriasis	0.000225	0.00151	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000225	0.00151	CcSEcCtD
Epinephrine—Hallucination—Betamethasone—psoriasis	0.000224	0.0015	CcSEcCtD
Epinephrine—Hallucination—Dexamethasone—psoriasis	0.000224	0.0015	CcSEcCtD
Epinephrine—Hypertension—Cyclosporine—psoriasis	0.000223	0.0015	CcSEcCtD
Epinephrine—Palpitations—Mycophenolate mofetil—psoriasis	0.000222	0.00149	CcSEcCtD
Epinephrine—Arrhythmia—Triamcinolone—psoriasis	0.000221	0.00149	CcSEcCtD
Epinephrine—Hyperglycaemia—Prednisone—psoriasis	0.000221	0.00148	CcSEcCtD
Epinephrine—Chest pain—Cyclosporine—psoriasis	0.000219	0.00148	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000218	0.00147	CcSEcCtD
Epinephrine—Hypertension—Mycophenolate mofetil—psoriasis	0.000217	0.00146	CcSEcCtD
Epinephrine—Erythema—Triamcinolone—psoriasis	0.000216	0.00145	CcSEcCtD
Epinephrine—Acute coronary syndrome—Prednisone—psoriasis	0.000215	0.00145	CcSEcCtD
Epinephrine—Chest pain—Mycophenolate mofetil—psoriasis	0.000214	0.00144	CcSEcCtD
Epinephrine—Myocardial infarction—Prednisone—psoriasis	0.000214	0.00144	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000213	0.00143	CcSEcCtD
Epinephrine—Nervous system disorder—Cyclosporine—psoriasis	0.000206	0.00139	CcSEcCtD
Epinephrine—Dizziness—Hydroxyurea—psoriasis	0.000205	0.00138	CcSEcCtD
Epinephrine—Skin disorder—Cyclosporine—psoriasis	0.000204	0.00137	CcSEcCtD
Epinephrine—Hyperhidrosis—Cyclosporine—psoriasis	0.000203	0.00137	CcSEcCtD
Epinephrine—Hypertension—Prednisolone—psoriasis	0.000203	0.00136	CcSEcCtD
Epinephrine—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000201	0.00135	CcSEcCtD
Epinephrine—Arrhythmia—Dexamethasone—psoriasis	0.000201	0.00135	CcSEcCtD
Epinephrine—Arrhythmia—Betamethasone—psoriasis	0.000201	0.00135	CcSEcCtD
Epinephrine—Tachycardia—Mycophenolate mofetil—psoriasis	0.0002	0.00135	CcSEcCtD
Epinephrine—Skin disorder—Mycophenolate mofetil—psoriasis	0.000199	0.00134	CcSEcCtD
Epinephrine—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.000198	0.00133	CcSEcCtD
Epinephrine—Hypertension—Hydrocortisone—psoriasis	0.000198	0.00133	CcSEcCtD
Epinephrine—Vomiting—Hydroxyurea—psoriasis	0.000197	0.00133	CcSEcCtD
Epinephrine—Haemoglobin—Prednisone—psoriasis	0.000197	0.00132	CcSEcCtD
Epinephrine—Haemorrhage—Prednisone—psoriasis	0.000196	0.00132	CcSEcCtD
Epinephrine—Erythema—Dexamethasone—psoriasis	0.000196	0.00132	CcSEcCtD
Epinephrine—Erythema—Betamethasone—psoriasis	0.000196	0.00132	CcSEcCtD
Epinephrine—Hallucination—Prednisone—psoriasis	0.000195	0.00131	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000194	0.0013	CcSEcCtD
Epinephrine—Insomnia—Cyclosporine—psoriasis	0.00019	0.00128	CcSEcCtD
Epinephrine—Paraesthesia—Cyclosporine—psoriasis	0.000189	0.00127	CcSEcCtD
Epinephrine—Somnolence—Cyclosporine—psoriasis	0.000187	0.00126	CcSEcCtD
Epinephrine—Tachycardia—Prednisolone—psoriasis	0.000187	0.00126	CcSEcCtD
Epinephrine—Hypertension—Triamcinolone—psoriasis	0.000186	0.00125	CcSEcCtD
Epinephrine—Insomnia—Mycophenolate mofetil—psoriasis	0.000186	0.00125	CcSEcCtD
Epinephrine—Hyperhidrosis—Prednisolone—psoriasis	0.000185	0.00124	CcSEcCtD
Epinephrine—Nausea—Hydroxyurea—psoriasis	0.000184	0.00124	CcSEcCtD
Epinephrine—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000184	0.00124	CcSEcCtD
Epinephrine—Nervous system disorder—Hydrocortisone—psoriasis	0.000183	0.00123	CcSEcCtD
Epinephrine—Tachycardia—Hydrocortisone—psoriasis	0.000182	0.00123	CcSEcCtD
Epinephrine—Somnolence—Mycophenolate mofetil—psoriasis	0.000182	0.00123	CcSEcCtD
Epinephrine—Drowsiness—Methotrexate—psoriasis	0.000182	0.00123	CcSEcCtD
Epinephrine—Flushing—Prednisone—psoriasis	0.000182	0.00122	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000182	0.00122	CcSEcCtD
Epinephrine—Skin disorder—Hydrocortisone—psoriasis	0.000182	0.00122	CcSEcCtD
Epinephrine—Hyperhidrosis—Hydrocortisone—psoriasis	0.000181	0.00122	CcSEcCtD
Epinephrine—Renal failure—Methotrexate—psoriasis	0.000179	0.00121	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000177	0.00119	CcSEcCtD
Epinephrine—Arrhythmia—Prednisone—psoriasis	0.000175	0.00118	CcSEcCtD
Epinephrine—Sweating—Methotrexate—psoriasis	0.000175	0.00118	CcSEcCtD
Epinephrine—Insomnia—Prednisolone—psoriasis	0.000173	0.00116	CcSEcCtD
Epinephrine—Dizziness—Mycophenolic acid—psoriasis	0.000172	0.00116	CcSEcCtD
Epinephrine—Paraesthesia—Prednisolone—psoriasis	0.000172	0.00116	CcSEcCtD
Epinephrine—Tachycardia—Triamcinolone—psoriasis	0.000172	0.00116	CcSEcCtD
Epinephrine—Mental disorder—Prednisone—psoriasis	0.000172	0.00115	CcSEcCtD
Epinephrine—Erythema—Prednisone—psoriasis	0.00017	0.00115	CcSEcCtD
Epinephrine—Hyperhidrosis—Triamcinolone—psoriasis	0.00017	0.00114	CcSEcCtD
Epinephrine—Insomnia—Hydrocortisone—psoriasis	0.000169	0.00114	CcSEcCtD
Epinephrine—Hypertension—Betamethasone—psoriasis	0.000169	0.00114	CcSEcCtD
Epinephrine—Hypertension—Dexamethasone—psoriasis	0.000169	0.00114	CcSEcCtD
Epinephrine—Paraesthesia—Hydrocortisone—psoriasis	0.000168	0.00113	CcSEcCtD
Epinephrine—Vomiting—Mycophenolic acid—psoriasis	0.000165	0.00111	CcSEcCtD
Epinephrine—Haemoglobin—Methotrexate—psoriasis	0.000164	0.00111	CcSEcCtD
Epinephrine—Haemorrhage—Methotrexate—psoriasis	0.000164	0.0011	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000161	0.00109	CcSEcCtD
Epinephrine—Insomnia—Triamcinolone—psoriasis	0.000159	0.00107	CcSEcCtD
Epinephrine—Paraesthesia—Triamcinolone—psoriasis	0.000158	0.00106	CcSEcCtD
Epinephrine—Nervous system disorder—Betamethasone—psoriasis	0.000157	0.00105	CcSEcCtD
Epinephrine—Nervous system disorder—Dexamethasone—psoriasis	0.000157	0.00105	CcSEcCtD
Epinephrine—Agitation—Prednisone—psoriasis	0.000157	0.00105	CcSEcCtD
Epinephrine—Tachycardia—Dexamethasone—psoriasis	0.000156	0.00105	CcSEcCtD
Epinephrine—Tachycardia—Betamethasone—psoriasis	0.000156	0.00105	CcSEcCtD
Epinephrine—Nausea—Mycophenolic acid—psoriasis	0.000154	0.00104	CcSEcCtD
Epinephrine—Hyperhidrosis—Betamethasone—psoriasis	0.000154	0.00104	CcSEcCtD
Epinephrine—Hyperhidrosis—Dexamethasone—psoriasis	0.000154	0.00104	CcSEcCtD
Epinephrine—Hypertension—Prednisone—psoriasis	0.000147	0.00099	CcSEcCtD
Epinephrine—Insomnia—Dexamethasone—psoriasis	0.000144	0.000972	CcSEcCtD
Epinephrine—Insomnia—Betamethasone—psoriasis	0.000144	0.000972	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000144	0.000969	CcSEcCtD
Epinephrine—Paraesthesia—Dexamethasone—psoriasis	0.000143	0.000965	CcSEcCtD
Epinephrine—Paraesthesia—Betamethasone—psoriasis	0.000143	0.000965	CcSEcCtD
Epinephrine—Mental disorder—Methotrexate—psoriasis	0.000143	0.000964	CcSEcCtD
Epinephrine—Erythema—Methotrexate—psoriasis	0.000142	0.000958	CcSEcCtD
Epinephrine—Dizziness—Cyclosporine—psoriasis	0.000139	0.000936	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Betamethasone—psoriasis	0.000138	0.000927	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000138	0.000927	CcSEcCtD
Epinephrine—Nervous system disorder—Prednisone—psoriasis	0.000136	0.000917	CcSEcCtD
Epinephrine—Tachycardia—Prednisone—psoriasis	0.000136	0.000913	CcSEcCtD
Epinephrine—Dizziness—Mycophenolate mofetil—psoriasis	0.000136	0.000913	CcSEcCtD
Epinephrine—Skin disorder—Prednisone—psoriasis	0.000135	0.000909	CcSEcCtD
Epinephrine—Hyperhidrosis—Prednisone—psoriasis	0.000134	0.000904	CcSEcCtD
Epinephrine—Vomiting—Cyclosporine—psoriasis	0.000134	0.0009	CcSEcCtD
Epinephrine—Vomiting—Mycophenolate mofetil—psoriasis	0.00013	0.000878	CcSEcCtD
Epinephrine—Dizziness—Prednisolone—psoriasis	0.000127	0.000851	CcSEcCtD
Epinephrine—Insomnia—Prednisone—psoriasis	0.000126	0.000846	CcSEcCtD
Epinephrine—Nausea—Cyclosporine—psoriasis	0.000125	0.00084	CcSEcCtD
Epinephrine—Paraesthesia—Prednisone—psoriasis	0.000125	0.00084	CcSEcCtD
Epinephrine—Dizziness—Hydrocortisone—psoriasis	0.000124	0.000831	CcSEcCtD
Epinephrine—Nausea—Mycophenolate mofetil—psoriasis	0.000122	0.00082	CcSEcCtD
Epinephrine—Chest pain—Methotrexate—psoriasis	0.000121	0.000816	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.00012	0.00081	CcSEcCtD
Epinephrine—Vomiting—Hydrocortisone—psoriasis	0.000119	0.000799	CcSEcCtD
Epinephrine—Dizziness—Triamcinolone—psoriasis	0.000116	0.000783	CcSEcCtD
Epinephrine—Nervous system disorder—Methotrexate—psoriasis	0.000114	0.000767	CcSEcCtD
Epinephrine—Nausea—Prednisolone—psoriasis	0.000114	0.000765	CcSEcCtD
Epinephrine—Skin disorder—Methotrexate—psoriasis	0.000113	0.000759	CcSEcCtD
Epinephrine—Hyperhidrosis—Methotrexate—psoriasis	0.000112	0.000756	CcSEcCtD
Epinephrine—Vomiting—Triamcinolone—psoriasis	0.000112	0.000753	CcSEcCtD
Epinephrine—Nausea—Hydrocortisone—psoriasis	0.000111	0.000747	CcSEcCtD
Epinephrine—Dizziness—Dexamethasone—psoriasis	0.000106	0.00071	CcSEcCtD
Epinephrine—Dizziness—Betamethasone—psoriasis	0.000106	0.00071	CcSEcCtD
Epinephrine—Insomnia—Methotrexate—psoriasis	0.000105	0.000707	CcSEcCtD
Epinephrine—Nausea—Triamcinolone—psoriasis	0.000105	0.000703	CcSEcCtD
Epinephrine—Paraesthesia—Methotrexate—psoriasis	0.000104	0.000702	CcSEcCtD
Epinephrine—Somnolence—Methotrexate—psoriasis	0.000103	0.000695	CcSEcCtD
Epinephrine—Vomiting—Dexamethasone—psoriasis	0.000102	0.000683	CcSEcCtD
Epinephrine—Vomiting—Betamethasone—psoriasis	0.000102	0.000683	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Methotrexate—psoriasis	0.0001	0.000675	CcSEcCtD
Epinephrine—Nausea—Betamethasone—psoriasis	9.49e-05	0.000638	CcSEcCtD
Epinephrine—Nausea—Dexamethasone—psoriasis	9.49e-05	0.000638	CcSEcCtD
Epinephrine—Dizziness—Prednisone—psoriasis	9.2e-05	0.000619	CcSEcCtD
Epinephrine—Vomiting—Prednisone—psoriasis	8.85e-05	0.000595	CcSEcCtD
Epinephrine—Nausea—Prednisone—psoriasis	8.26e-05	0.000556	CcSEcCtD
Epinephrine—Dizziness—Methotrexate—psoriasis	7.69e-05	0.000517	CcSEcCtD
Epinephrine—Vomiting—Methotrexate—psoriasis	7.39e-05	0.000497	CcSEcCtD
Epinephrine—Nausea—Methotrexate—psoriasis	6.91e-05	0.000464	CcSEcCtD
Epinephrine—ADRA2B—Hemostasis—NOS2—psoriasis	3.03e-05	0.000334	CbGpPWpGaD
Epinephrine—ADRA2A—G alpha (i) signalling events—CXCL8—psoriasis	3.03e-05	0.000334	CbGpPWpGaD
Epinephrine—TNF—Developmental Biology—TYK2—psoriasis	3.03e-05	0.000334	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by GPCR—TYK2—psoriasis	3.02e-05	0.000332	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—CCL20—psoriasis	3.01e-05	0.000331	CbGpPWpGaD
Epinephrine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.97e-05	0.000327	CbGpPWpGaD
Epinephrine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.92e-05	0.000322	CbGpPWpGaD
Epinephrine—ADRBK1—GPCR downstream signaling—CXCL8—psoriasis	2.89e-05	0.000319	CbGpPWpGaD
Epinephrine—ADRA2C—Hemostasis—NOS2—psoriasis	2.83e-05	0.000312	CbGpPWpGaD
Epinephrine—PAH—Disease—STAT3—psoriasis	2.8e-05	0.000308	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—NDUFA5—psoriasis	2.78e-05	0.000307	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—CYP2S1—psoriasis	2.77e-05	0.000305	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—TYK2—psoriasis	2.76e-05	0.000304	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—CCL20—psoriasis	2.74e-05	0.000302	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CCL20—psoriasis	2.72e-05	0.000299	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CCL20—psoriasis	2.68e-05	0.000295	CbGpPWpGaD
Epinephrine—ADRA1D—GPCR ligand binding—CXCL8—psoriasis	2.68e-05	0.000295	CbGpPWpGaD
Epinephrine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.67e-05	0.000294	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—CARM1—psoriasis	2.65e-05	0.000292	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by GPCR—CXCL8—psoriasis	2.63e-05	0.000289	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.6e-05	0.000286	CbGpPWpGaD
Epinephrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.59e-05	0.000286	CbGpPWpGaD
Epinephrine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—psoriasis	2.59e-05	0.000285	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—IFNG—psoriasis	2.58e-05	0.000284	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—CARM1—psoriasis	2.58e-05	0.000284	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—TYK2—psoriasis	2.55e-05	0.00028	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—SOCS1—psoriasis	2.54e-05	0.00028	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CCL20—psoriasis	2.54e-05	0.000279	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CCL20—psoriasis	2.5e-05	0.000275	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—CD4—psoriasis	2.49e-05	0.000275	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—CARM1—psoriasis	2.47e-05	0.000272	CbGpPWpGaD
Epinephrine—ADRB1—GPCR ligand binding—CXCL8—psoriasis	2.44e-05	0.000269	CbGpPWpGaD
Epinephrine—ADRB3—Signaling by GPCR—TYK2—psoriasis	2.42e-05	0.000267	CbGpPWpGaD
Epinephrine—ADRA2B—GPCR ligand binding—CXCL8—psoriasis	2.42e-05	0.000266	CbGpPWpGaD
Epinephrine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.41e-05	0.000265	CbGpPWpGaD
Epinephrine—ADRB2—GPCR ligand binding—CXCL8—psoriasis	2.39e-05	0.000263	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—CYP2S1—psoriasis	2.37e-05	0.000261	CbGpPWpGaD
Epinephrine—TNF—Developmental Biology—NFKB1—psoriasis	2.36e-05	0.00026	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—LEP—psoriasis	2.34e-05	0.000257	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—APOE—psoriasis	2.34e-05	0.000257	CbGpPWpGaD
Epinephrine—ADRB3—GPCR downstream signaling—CXCL8—psoriasis	2.32e-05	0.000256	CbGpPWpGaD
Epinephrine—ADRBK1—Innate Immune System—IL6—psoriasis	2.32e-05	0.000255	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—CD4—psoriasis	2.3e-05	0.000254	CbGpPWpGaD
Epinephrine—ADRA2A—Hemostasis—NOS2—psoriasis	2.3e-05	0.000253	CbGpPWpGaD
Epinephrine—ADRA2C—GPCR ligand binding—CXCL8—psoriasis	2.26e-05	0.000249	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—JUN—psoriasis	2.23e-05	0.000246	CbGpPWpGaD
Epinephrine—ADRA1B—GPCR ligand binding—CXCL8—psoriasis	2.22e-05	0.000245	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CCL20—psoriasis	2.22e-05	0.000244	CbGpPWpGaD
Epinephrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.21e-05	0.000244	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—NFKBIA—psoriasis	2.18e-05	0.00024	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—NFKB1—psoriasis	2.15e-05	0.000237	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—NDUFA5—psoriasis	2.15e-05	0.000237	CbGpPWpGaD
Epinephrine—TNF—Developmental Biology—VEGFA—psoriasis	2.14e-05	0.000236	CbGpPWpGaD
Epinephrine—TNF—Developmental Biology—STAT3—psoriasis	2.12e-05	0.000234	CbGpPWpGaD
Epinephrine—ADRB3—Signaling by GPCR—CXCL8—psoriasis	2.11e-05	0.000232	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—CARM1—psoriasis	2.09e-05	0.000231	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CCL20—psoriasis	2.06e-05	0.000227	CbGpPWpGaD
Epinephrine—ADRA1A—GPCR ligand binding—CXCL8—psoriasis	1.97e-05	0.000217	CbGpPWpGaD
Epinephrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.97e-05	0.000217	CbGpPWpGaD
Epinephrine—PAH—Disease—IL6—psoriasis	1.95e-05	0.000215	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—STAT3—psoriasis	1.93e-05	0.000213	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—LEP—psoriasis	1.88e-05	0.000207	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—APOE—psoriasis	1.88e-05	0.000207	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR ligand binding—CXCL8—psoriasis	1.84e-05	0.000202	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.83e-05	0.000201	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—TYK2—psoriasis	1.78e-05	0.000196	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—STAT3—psoriasis	1.78e-05	0.000196	CbGpPWpGaD
Epinephrine—ADRA2B—Hemostasis—VEGFA—psoriasis	1.76e-05	0.000193	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—NFKBIA—psoriasis	1.75e-05	0.000192	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—SOCS1—psoriasis	1.66e-05	0.000182	CbGpPWpGaD
Epinephrine—ADRA2C—Hemostasis—VEGFA—psoriasis	1.64e-05	0.000181	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—CAT—psoriasis	1.63e-05	0.00018	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—CAT—psoriasis	1.59e-05	0.000175	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—TYK2—psoriasis	1.58e-05	0.000174	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—CXCL8—psoriasis	1.55e-05	0.000171	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—CAT—psoriasis	1.52e-05	0.000167	CbGpPWpGaD
Epinephrine—ADRA1D—GPCR downstream signaling—CXCL8—psoriasis	1.51e-05	0.000167	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—SOCS1—psoriasis	1.51e-05	0.000166	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—SOCS1—psoriasis	1.5e-05	0.000165	CbGpPWpGaD
Epinephrine—TNF—Developmental Biology—IL6—psoriasis	1.48e-05	0.000163	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by GPCR—IL6—psoriasis	1.48e-05	0.000163	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—SOCS1—psoriasis	1.48e-05	0.000163	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.45e-05	0.00016	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—JUN—psoriasis	1.44e-05	0.000159	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—TYK2—psoriasis	1.44e-05	0.000158	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—TYK2—psoriasis	1.43e-05	0.000158	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—TYK2—psoriasis	1.43e-05	0.000157	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—TYK2—psoriasis	1.41e-05	0.000155	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—SOCS1—psoriasis	1.4e-05	0.000154	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—NFKB1—psoriasis	1.39e-05	0.000153	CbGpPWpGaD
Epinephrine—ADRB1—GPCR downstream signaling—CXCL8—psoriasis	1.38e-05	0.000152	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—CXCL8—psoriasis	1.37e-05	0.000151	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—SOCS1—psoriasis	1.37e-05	0.000151	CbGpPWpGaD
Epinephrine—ADRA2B—GPCR downstream signaling—CXCL8—psoriasis	1.37e-05	0.00015	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—CARM1—psoriasis	1.35e-05	0.000149	CbGpPWpGaD
Epinephrine—ADRB2—GPCR downstream signaling—CXCL8—psoriasis	1.35e-05	0.000149	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—IL6—psoriasis	1.35e-05	0.000149	CbGpPWpGaD
Epinephrine—ADRA2A—Hemostasis—VEGFA—psoriasis	1.33e-05	0.000147	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—TYK2—psoriasis	1.33e-05	0.000147	CbGpPWpGaD
Epinephrine—ADRA2B—Hemostasis—TP53—psoriasis	1.33e-05	0.000146	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—TYK2—psoriasis	1.31e-05	0.000144	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—CAT—psoriasis	1.29e-05	0.000142	CbGpPWpGaD
Epinephrine—ADRA2C—GPCR downstream signaling—CXCL8—psoriasis	1.28e-05	0.000141	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—APOE—psoriasis	1.27e-05	0.00014	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.26e-05	0.000139	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—VEGFA—psoriasis	1.26e-05	0.000139	CbGpPWpGaD
Epinephrine—ADRA1B—GPCR downstream signaling—CXCL8—psoriasis	1.26e-05	0.000138	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—CXCL8—psoriasis	1.25e-05	0.000138	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—STAT3—psoriasis	1.25e-05	0.000138	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—CXCL8—psoriasis	1.25e-05	0.000137	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—IL6—psoriasis	1.25e-05	0.000137	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—CXCL8—psoriasis	1.24e-05	0.000137	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.24e-05	0.000137	CbGpPWpGaD
Epinephrine—ADRA2C—Hemostasis—TP53—psoriasis	1.24e-05	0.000137	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—APOE—psoriasis	1.23e-05	0.000136	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—CXCL8—psoriasis	1.23e-05	0.000135	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—APOE—psoriasis	1.22e-05	0.000135	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—LEP—psoriasis	1.22e-05	0.000135	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—SOCS1—psoriasis	1.22e-05	0.000134	CbGpPWpGaD
Epinephrine—ADRB3—Signaling by GPCR—IL6—psoriasis	1.19e-05	0.000131	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—APOE—psoriasis	1.18e-05	0.00013	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—TYK2—psoriasis	1.16e-05	0.000128	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—CXCL8—psoriasis	1.16e-05	0.000128	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—JUN—psoriasis	1.16e-05	0.000128	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—CARM1—psoriasis	1.16e-05	0.000127	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—CXCL8—psoriasis	1.14e-05	0.000126	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—NFKBIA—psoriasis	1.14e-05	0.000125	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—SOCS1—psoriasis	1.13e-05	0.000125	CbGpPWpGaD
Epinephrine—ADRA1A—GPCR downstream signaling—CXCL8—psoriasis	1.12e-05	0.000123	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—NFKB1—psoriasis	1.12e-05	0.000123	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—APOE—psoriasis	1.11e-05	0.000123	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—LEP—psoriasis	1.11e-05	0.000123	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—PPARG—psoriasis	1.1e-05	0.000122	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—APOE—psoriasis	1.1e-05	0.000121	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—LEP—psoriasis	1.1e-05	0.000121	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—LEP—psoriasis	1.09e-05	0.00012	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—APOE—psoriasis	1.09e-05	0.00012	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—TYK2—psoriasis	1.08e-05	0.000119	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.08e-05	0.000119	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—PPARG—psoriasis	1.07e-05	0.000118	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—NFKBIA—psoriasis	1.04e-05	0.000114	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR downstream signaling—CXCL8—psoriasis	1.04e-05	0.000114	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—LEP—psoriasis	1.03e-05	0.000113	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—APOE—psoriasis	1.03e-05	0.000113	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—PPARG—psoriasis	1.03e-05	0.000113	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—NFKBIA—psoriasis	1.03e-05	0.000113	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—NFKBIA—psoriasis	1.02e-05	0.000112	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—APOE—psoriasis	1.01e-05	0.000112	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—LEP—psoriasis	1.01e-05	0.000112	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—CXCL8—psoriasis	1.01e-05	0.000112	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—VEGFA—psoriasis	1.01e-05	0.000111	CbGpPWpGaD
Epinephrine—ADRA2A—Hemostasis—TP53—psoriasis	1.01e-05	0.000111	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—STAT3—psoriasis	1e-05	0.00011	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—APOE—psoriasis	1e-05	0.00011	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—NFKBIA—psoriasis	9.6e-06	0.000106	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—TP53—psoriasis	9.53e-06	0.000105	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—NFKBIA—psoriasis	9.45e-06	0.000104	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—CXCL8—psoriasis	9.42e-06	0.000104	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—TYK2—psoriasis	9.33e-06	0.000103	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—APOE—psoriasis	9.01e-06	9.92e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—LEP—psoriasis	9.01e-06	9.92e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CARM1—psoriasis	8.92e-06	9.83e-05	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—IL6—psoriasis	8.72e-06	9.6e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—PPARG—psoriasis	8.72e-06	9.6e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—TYK2—psoriasis	8.5e-06	9.36e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—TYK2—psoriasis	8.42e-06	9.27e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—NFKBIA—psoriasis	8.4e-06	9.24e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—LEP—psoriasis	8.37e-06	9.22e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—APOE—psoriasis	8.37e-06	9.22e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—CAT—psoriasis	8.32e-06	9.16e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—TYK2—psoriasis	8.31e-06	9.15e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—CXCL8—psoriasis	8.12e-06	8.94e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—TYK2—psoriasis	7.87e-06	8.66e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—NFKBIA—psoriasis	7.8e-06	8.59e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—TYK2—psoriasis	7.74e-06	8.52e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—IL6—psoriasis	7.72e-06	8.5e-05	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—TP53—psoriasis	7.65e-06	8.42e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—JUN—psoriasis	7.55e-06	8.31e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—CXCL8—psoriasis	7.4e-06	8.15e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CXCL8—psoriasis	7.33e-06	8.07e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—NFKB1—psoriasis	7.27e-06	8e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CXCL8—psoriasis	7.24e-06	7.97e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—CAT—psoriasis	7.11e-06	7.83e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—IL6—psoriasis	7.04e-06	7.75e-05	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—IL6—psoriasis	7e-06	7.71e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—IL6—psoriasis	6.97e-06	7.68e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—IL6—psoriasis	6.88e-06	7.58e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—JUN—psoriasis	6.88e-06	7.57e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—TYK2—psoriasis	6.88e-06	7.57e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CXCL8—psoriasis	6.85e-06	7.54e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—JUN—psoriasis	6.82e-06	7.51e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CXCL8—psoriasis	6.74e-06	7.42e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—JUN—psoriasis	6.73e-06	7.41e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—NFKB1—psoriasis	6.62e-06	7.29e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—VEGFA—psoriasis	6.6e-06	7.26e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—NFKB1—psoriasis	6.56e-06	7.22e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—STAT3—psoriasis	6.53e-06	7.19e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—IL6—psoriasis	6.51e-06	7.17e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—NFKB1—psoriasis	6.48e-06	7.13e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—APOE—psoriasis	6.47e-06	7.12e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—IL6—psoriasis	6.41e-06	7.06e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—TYK2—psoriasis	6.39e-06	7.04e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—JUN—psoriasis	6.37e-06	7.01e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—JUN—psoriasis	6.27e-06	6.9e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—NFKB1—psoriasis	6.13e-06	6.75e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—NFKB1—psoriasis	6.03e-06	6.64e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—VEGFA—psoriasis	6.01e-06	6.62e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CXCL8—psoriasis	5.99e-06	6.59e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—VEGFA—psoriasis	5.96e-06	6.56e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—STAT3—psoriasis	5.95e-06	6.55e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—STAT3—psoriasis	5.9e-06	6.49e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—VEGFA—psoriasis	5.88e-06	6.47e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—STAT3—psoriasis	5.82e-06	6.41e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—IL6—psoriasis	5.69e-06	6.27e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PPARG—psoriasis	5.63e-06	6.2e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—JUN—psoriasis	5.57e-06	6.13e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CXCL8—psoriasis	5.56e-06	6.13e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—VEGFA—psoriasis	5.56e-06	6.13e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—APOE—psoriasis	5.53e-06	6.09e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—STAT3—psoriasis	5.51e-06	6.06e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CAT—psoriasis	5.49e-06	6.04e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—VEGFA—psoriasis	5.47e-06	6.03e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—STAT3—psoriasis	5.42e-06	5.97e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—NFKB1—psoriasis	5.36e-06	5.9e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—IL6—psoriasis	5.29e-06	5.82e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—JUN—psoriasis	5.17e-06	5.69e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—TP53—psoriasis	4.98e-06	5.49e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—NFKB1—psoriasis	4.98e-06	5.48e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—VEGFA—psoriasis	4.86e-06	5.35e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—STAT3—psoriasis	4.81e-06	5.3e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PPARG—psoriasis	4.81e-06	5.3e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—IL6—psoriasis	4.56e-06	5.02e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—TP53—psoriasis	4.54e-06	5e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—VEGFA—psoriasis	4.52e-06	4.98e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—TP53—psoriasis	4.5e-06	4.95e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—STAT3—psoriasis	4.47e-06	4.93e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—TP53—psoriasis	4.44e-06	4.89e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—APOE—psoriasis	4.27e-06	4.7e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—TP53—psoriasis	4.2e-06	4.63e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—IL6—psoriasis	4.16e-06	4.58e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—TP53—psoriasis	4.14e-06	4.55e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—IL6—psoriasis	4.12e-06	4.54e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—IL6—psoriasis	4.07e-06	4.48e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—IL6—psoriasis	3.85e-06	4.24e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—IL6—psoriasis	3.79e-06	4.17e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PPARG—psoriasis	3.72e-06	4.09e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—TP53—psoriasis	3.67e-06	4.05e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—TP53—psoriasis	3.41e-06	3.76e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—IL6—psoriasis	3.36e-06	3.7e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—IL6—psoriasis	3.12e-06	3.44e-05	CbGpPWpGaD
